| People report they can get primary care when they need it |
This measure provides details on the percentage of people who say they receive care from a GP or nurse when they need it. |
New Zealand primary care patient experience survey, Te Tāhū Hauora Health Quality & Safety Commission, National Enrolment Service (NES), Ministry of Health |
Health Quality & Safety Commission | Te Tāhū Hauora |
|
| People aged under 25 years able to access specialist mental health services within three weeks of referral |
This measure details the percentage of new clients aged under 25 years seen within three weeks of referral to mental health services. We know there are pressures on child and youth services, and some children and young people have to wait before accessing the help they need. The onset of serious mental illness mostly occurs before the age of 25 years, and crosses child and adolescent and adult service boundaries. It is important to focus on the specific needs of young people presenting with a first episode of illness. This indicator aims to lift performance and support more timely access for children and young people. |
Programme for the Integration of Mental Health Data (PRIMHD), Ministry of Health |
Health Quality & Safety Commission | Te Tāhū Hauora |
|
| Immunisation rate for children at 24 months old |
This measure details the percentage of children who have all their age-appropriate schedule vaccinations by the time they are two years old. Timely immunisations ensure children are protected against harmful and avoidable diseases. The childhood immunisation programme is a series of vaccines that are offered free to babies and young children. The first vaccinations occur when the child is six weeks old. This programme is part of the national immunisation schedule. |
National Immunisation Register (NIR), Ministry of Health |
Health Quality & Safety Commission | Te Tāhū Hauora |
|
| Gout prevalence |
This measure details the prevalence of identified gout in those enrolled with primary health organisations. Rates of gout are particularly high in Māori and Pacific males, meaning districts with a high Māori and/or Pacific population have higher prevalence. |
National Minimum Dataset (NMDS), Pharmaceutical Collection (PHARMS), Primary Health Organisation Enrolment Collection, Mortality Collection, NZ Cancer Registry, Ministry of Health, National Population Projection - Stats NZ |
Health Quality & Safety Commission | Te Tāhū Hauora |
|
| Regularly dispensed a urate-lowering therapy |
This measure shows the percentage of people with identified gout who received urate-lowering therapy regularly. Long-term urate-lowering therapy is used to prevent gout flares and prevent tophus formation, bony erosions and permanent disability in people with gout. Many studies have demonstrated underutilisation of urate-lowering therapy. |
National Minimum Dataset (NMDS), Pharmaceutical Collection (PHARMS), PHO Enrolment Collection, Mortality Collection, NZ Cancer Registry, Ministry of Health, National Population Projection - Stats NZ |
Health Quality & Safety Commission | Te Tāhū Hauora |
|
| Serum urate test within six months of urate-lowering therapy |
This measure shows the percentage of people who had serum urate testing in the six months following urate-lowering therapy dispensing. Best practice guidelines recommend that people with gout who are prescribed urate-lowering therapy should have their serum urate level monitored at least every six months. Long-term urate-lowering therapy is not recommended for people with asymptomatic hyperuricaemia. |
National Minimum Dataset (NMDS), Pharmaceutical Collection (PHARMS), PHO Enrolment Collection, Mortality Collection, NZ Cancer Registry, Ministry of Health, National Population Projection - Stats NZ |
Health Quality & Safety Commission | Te Tāhū Hauora |
|
| Ambulatory sensitive hospitalisations for adults (age range 45–64 years) |
This measure details the rate of hospital admissions for people aged 45–64 years for an illness that might have been prevented or better managed in the community. Ambulatory sensitive hospitalisations are mostly acute admissions that are considered potentially reducible through prophylactic or therapeutic interventions deliverable in a primary care setting. |
National Minimum Dataset (NMDS), Ministry of Health, Estimated Resident Population Projections, Stats NZ |
Health Quality & Safety Commission | Te Tāhū Hauora |
|
| Dispensed prednisone, colchicine or a non-steroidal anti-inflammatory drug without urate-lowering therapy |
This measure shows the percentage of people with identified gout who were dispensed any of colchicine, prednisone or funded non-steroidal anti-inflammatory drugs (NSAIDs), but not dispensed urate-lowering therapy in a year. Acute gout flares are treated with colchicine, oral corticosteroids such as prednisone or NSAIDs. This measure may reflect people experiencing acute gout flares who are not on long-term preventive therapy for gout. Gout management guidelines state that people experiencing frequent (two or more) acute gout flares per year should be offered long-term urate-lowering therapy. Although NSAIDs are effective at treating acute gout flares, these medicines have considerable side effects including kidney injury and peptic ulcer disease. |
National Minimum Dataset (NMDS), Pharmaceutical Collection (PHARMS), PHO Enrolment Collection, Mortality Collection, NZ Cancer Registry, Ministry of Health, National Population Projection - Stats NZ |
Health Quality & Safety Commission | Te Tāhū Hauora |
|
| Dispensed prednisone, colchicine or a non-steroidal anti-inflammatory drug |
This measure shows the percentage of people with identified gout who were dispensed any of colchicine, prednisone or funded non-steroidal anti-inflammatory drugs (NSAIDs) in a year. Acute gout flares are treated with colchicine, oral corticosteroids such as prednisone or NSAIDs. Gout management guidelines state that people experiencing frequent (two or more) acute gout flares per year should be offered long-term urate-lowering therapy. Although NSAIDs are effective at treating acute gout flares, these medicines have considerable side effects including kidney injury and peptic ulcer disease. |
National Minimum Dataset (NMDS), Pharmaceutical Collection (PHARMS), PHO Enrolment Collection, Mortality Collection, NZ Cancer Registry, Ministry of Health, National Population Projection - Stats NZ |
Health Quality & Safety Commission | Te Tāhū Hauora |
|
| Dispensed a non-steroidal anti-inflammatory drug without urate-lowering therapy |
This measure shows the percentage of people with identified gout who were dispensed funded non-steroidal anti-inflammatory drugs (NSAIDs) but not dispensed urate-lowering therapy. While it is not known whether it was gout that led to an NSAID being dispensed, high rates of NSAID dispensing without urate-lowering therapy use may reflect people using NSAIDs to manage their acute gout flares. International best practice indicates that people experiencing frequent gout flares (two or more per year) should be offered long-term urate-lowering therapy. Large variation may reflect patient preference and/or variable clinical practice. |
National Minimum Dataset (NMDS), Pharmaceutical Collection (PHARMS), PHO Enrolment Collection, Mortality Collection, NZ Cancer Registry, Ministry of Health, National Population Projection - Stats NZ |
Health Quality & Safety Commission | Te Tāhū Hauora |
|
